Skip to main content
. Author manuscript; available in PMC: 2023 Mar 23.
Published in final edited form as: Nat Biomed Eng. 2022 Aug 19;6(8):992–1003. doi: 10.1038/s41551-022-00925-y

Fig. 4 |. MIPSA analysis of autoantibodies in severe COVID-19.

Fig. 4 |

a, Box plots showing total numbers of autoreactive proteins in plasma from healthy controls (median 69.0 +/− s.d. of 36.3), mild-moderate COVID-19 patients (median 60.5 +/− s.d. of 44.7), or severe COVID-19 patients (median 106.0 +/− s.d. of 67.6). Boxes indicate quartiles and * indicates p = 0.02 and p = 0.05, respectively from a one-tailed t-test to compare means. b, Hierarchal cluster map of all proteins represented by at least 2 reactive UCIs in at least 1 severe COVID-19 plasma, but not more than 1 control (healthy or mild-moderate COVID-19 plasma). c, MIPSA analysis of autoantibodies in 10 inclusion body myositis (IBM) patients and 10 healthy controls (HCs), using the hORFeome library. Fold change of IPed 5’-nucleotidase, cytosolic 1A (NT5C1A), measured both as UCI-qPCR fold change (relative to average of 10 HCs) and as sequencing fold change (relative to mock IPs).